GSK "LIANOZOVO", Moscow

Economic indicators

Net profit (RAS) of GSK LIANOZOVO dropped in 2024 by 10.70% to 317.00 thousand RUB from 355.00 thousand RUB over the same period in 2023, the company informed.

Revenue increased in the accounting period by 1.75% to 3.73 million RUB from 3.67 million RUB over 2023; cost of goods sold grew by 3.35% to 3.36 million RUB from 3.25 million RUB; sales profit fell by 10.77% to 373.00 thousand RUB from 418.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO dropped in 2023 by 46.78% to 355.00 thousand RUB from 667.00 thousand RUB over the same period in 2022, the company informed.

Revenue decreased in the accounting period by 9.34% to 3.67 million RUB from 4.05 million RUB in 2022; cost of goods sold remained at the same level amounting to 3.25 million RUB compared to 3.26 million RUB; sales profit fell by 46.75% to 418.00 thousand RUB from 785.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO grew over 2022 2.21 times to 667.00 thousand RUB from 302.00 thousand RUB over 2021, the company informed.

Revenue increased in the accounting period by 15.28% to 4.05 million RUB from 3.51 million RUB over 2021; cost of goods sold grew by 3.36% to 3.26 million RUB from 3.15 million RUB; sales profit went up 2.21 times to 785.00 thousand RUB from 355.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO dropped in 2021 by 3.21% to 302.00 thousand RUB from 312.00 thousand RUB over the same period in 2020, the company informed.

Revenue increased in the accounting period by 14.26% to 3.51 million RUB from 3.07 million RUB over 2020; cost of goods sold grew by 15.74% to 3.15 million RUB from 2.73 million RUB; sales profit went up by 2.60% to 355.00 thousand RUB from 346.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO grew over 2020 by 15.99% to 312.00 thousand RUB from 269.00 thousand RUB over 2019, the company informed.

Revenue increased in the accounting period by 2.26% to 3.07 million RUB from 3.00 million RUB over 2019; cost of goods sold grew by 0.81% to 2.73 million RUB from 2.70 million RUB; sales profit went up by 15.33% to 346.00 thousand RUB from 300.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO dropped in 2019 by 36.56% to 269.00 thousand RUB from 424.00 thousand RUB over the same period in 2018, the company informed.

Revenue decreased in the accounting period by 32.35% to 3.00 million RUB from 4.44 million RUB in 2018; cost of goods sold decreased by 31.91% to 2.70 million RUB from 3.97 million RUB; sales profit fell by 36.03% to 300.00 thousand RUB from 469.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO grew over 2018 by 28.48% to 424.00 thousand RUB from 330.00 thousand RUB over 2017, the company informed.

Revenue increased in the accounting period by 3.71% to 4.44 million RUB from 4.28 million RUB over 2017; cost of goods sold grew by 2.00% to 3.97 million RUB from 3.89 million RUB; sales profit went up by 20.88% to 469.00 thousand RUB from 388.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO dropped in 2017 by 38.32% to 330.00 thousand RUB from 535.00 thousand RUB over the same period in 2016, the company informed.

Revenue increased in the accounting period by 11.66% to 4.28 million RUB from 3.83 million RUB over 2016; cost of goods sold grew by 9.66% to 3.89 million RUB from 3.55 million RUB; sales profit went up by 36.62% to 388.00 thousand RUB from 284.00 thousand RUB.

Net profit (RAS) of GSK LIANOZOVO grew over 2016 by 5.94% to 535.00 thousand RUB from 505.00 thousand RUB over 2015, the company informed.

Revenue increased in the accounting period by 18.63% to 3.83 million RUB from 3.23 million RUB over 2015; cost of goods sold grew by 12.67% to 3.55 million RUB from 3.15 million RUB; sales profit went up 3.51 times to 284.00 thousand RUB from 81.00 thousand RUB.

Companies in the region

• GAYSA
• VITA-TRANSAVTO
• AKADEMPRIBOR"
• KAPITAL
• PROMAKFES